Background: Studies investigating the therapeutic applications of transcranial direct current stimulation (tDCS) in the treatment of age-related neurodegenerative disease have been promising. However, exclusion criteria for these studies invariably disqualify patients implanted with internal cardiac pacemakers, citing safety concerns. Because the majority of cardiac pacemaker implantees are over 65, this criterion may limit candidacy for tDCS based research and/or treatment of age-related neurodegenerative disease. Objective/Hypothesis: We will test the hypothesis that tDCS impacts pacemaker function. Strong electrical potentials, such as those generated by external defibrillators (~500 V,~10 A), are known to occasionally damage pacemaker circuitry and software, but it seems unlikely tDCS would damage a pacemaker because it involves about 1/200th the energy (~12 V,~2 mA) of an external defibrillator. Methods: We delivered tDCS to seven participants (ages 70e92) with bipolar non-dependent pacemakers and subsequently collected data from the internal memory of the pacemakers to assess the tDCS signal detection, as well as alterations in mode switches, impedance levels, and pacing. Subsequently, similar assessments were carried out in participants who were pacemaker-dependent (ages 89e91). Results: After a review of the recordings, it was found that tDCS had no impact on the non-dependant, as well as the dependent, pacemakers. There were zero mode switches nor any impact on impedance levels. Conclusion: Results in this small series of cases found no evidence that tDCS interferes with the function of the pacemakers and suggests tDCS can be delivered to patients equipped with a cardiac pacemaker. Further studies are needed to generalize these results to other pacemakers.
Introduction
Transcranial direct current stimulation (tDCS) is a non-invasive form of neurostimulation that has shown promise as an ancillary therapy in multiple domains including depression [1] , stroke recovery [2] , and neurodegenerative diseases such as Alzheimer's disease (for a review, please see Priori et al., 2013 [3] ). In the case of neurodegenerative disease, observed improvement is especially exciting as formal cures or treatments are absent for various conditions. At the same time, tDCS should be given in a manner that is safe and effective with appropriate exclusion criteria to ensure best practices. For example, individuals with implanted devices (e.g., shunts, plates) are excluded from receiving tDCS because the implant can interfere with tDCS flow or vice-versa, leaving it unclear how electrodes should be positioned for these patients [4] . Exclusion criteria should also be thoroughly validated to ensure that people who could benefit from tDCS are excluded for sound reasons. However, many of the current exclusion criteria seem to be carried over from transcranial magnetic stimulation (TMS) protocols despite TMS being an unbound magnetic pulse in contrast to tDCS which is a direct current between two electrodes. As remarked by Thair, Holloway, Newport, and Smith [5] : "these criteria are largely based on TMS protocols, and therefore may not all share equal relevance to tDCS paradigms".
In this paper, we conduct a proof of concept study to discuss the hypothesis that tDCS can interfere with the performance of pacemakers. We consider this current criterion worthy of investigation due to studies reporting a benefit from tDCS for people with a neurodegenerative disease [6] . People with this illness generally belong to an age cohort where an implanted pacemaker is increasingly common [7] . Furthermore, considering the world's aging population, it can be envisioned that there will be an increasing number of people who have both a pacemaker and a neurodegenerative disease. Excluding individuals where the risks outweigh the benefits is good practice; but denying people a possible therapy in the face of a debilitating illness also requires verification that the risks do outweigh the possible benefits. We are unaware of any study that has verified that tDCS does poses a risk for pacemakers; thus, we investigated to what extent tDCS stimulation can impact the performance of a cardiac pacemaker.
In TMS, the exclusion criterion for pacemakers concerns the unbound magnetic pulse because pacemakers have been known to malfunction in the presence of strong electromagnetic fields [8] . However, electromagnetic fields known to cause pacemaker malfunction always involve intensities much higher than those produced by tDCS; although there is evidence that TMS for people with pacemakers can be safe under certain conditions [9] . Patients implanted with pacemakers are advised to avoid magnetic fields inherent to activities like magnetic resonance imaging and arc welding. In these activities, the minimum magnetic field intensities are 1.5 T and 0.35 mT respectively [10] . In contrast, the maximum magnetic field strength that an implanted pacemaker could encounter in a tDCS session (calculated based on a wire carrying 2 mA within 1 cm of pacemaker) would be 7.9 mT 1 [11] . This is about 1/200 the strength of these other magnetic fields. Similarly, strong electrical potentials, such as those generated by external defibrillators (~500 V,~10 A), are also known to occasionally damage pacemaker circuitry and software, and even cause burn trauma to the cardiac-electrode interface [12, 13] . However, tDCS stimulation involves about 1/200th the energy (~12 V,~2 mA) of an external defibrillator. Finally, imaging studies of human tDCS procedures have revealed that electrical potentials resulting from stimulation are limited to tissues proximal to electrode sites and to elements of the central nervous system between sites whereas a pacemaker delivers stimulation through cardiac or pericardial tissues [14] . In summary, it is unlikely that the energy levels transmitted by tDCS will negatively impact modern pacemakers.
It can also be theorized that the electrical current produced by two electrodes placed on the scalp will be safe for pacemakers because the current will restrict itself to the skull rather than venture toward the heart. A riskier montage would involve an extracephalic position such as the deltoid muscle, where the probability that the current will come close to the heart is greater. Therefore, to maximally stress the pacemaker with potential tDCS interference effects, in the current study, we avoided testing montages where both electrodes were placed on the scalp as the current in such conditions was expected to stay within the skull and remain distant from the heart. Instead, participants completed two tDCS montages where the current was expected to be more proximate to the heart: anode electrode over the left or right dorsolateral prefrontal cortex (DLPFC) area with the cathode electrode over the contralateral deltoid muscle. In these conditions, the tDCS current was predicted to approach the heart when transferring from the central nervous system to the peripheral (somatic) nervous system. We also examined if polarity mattered by having participants complete a third montage where the cathode was placed on the left DLPFC and the anode over the right deltoid muscle. Subsequent interrogation of participants' pacemakers would check for interference effects.
To avoid any potential risk to participants, we recruited participants with modern pacemakers that were non-dependent and bipolar. By selecting participants with modern devices, we also ensured the presence of pacemakers with their own internal memory that could record all EM signals detected and classify them. For this reason, before and after examinations for each individual session were unnecessary because the pacemaker would have a continuous recording of all three sessions. Thus, we made use of these recordings to interrogate the pacemaker: scrolled through its memory to find out what (if any) of the tDCS signal was detected and how it was interpreted, even if the pacemaker was never called upon to pace. Assuming we found an absence of interference effects, we would repeat the study with participants living with dependent pacemakers to generalize our results beyond non-dependent pacemakers. Because our study was focused exclusively on the impact of tDCS on pacemaker function, we chose to restrict our analyses to pacemaker measurements and omit additional clinical measurements. There was a strong possibility that any clinical measures or tests could cause unnecessary stress on the participants and is considered unwarranted by the study goals.
Study 1: Non-dependent pacemakers

Material and methods
Participants
Seven participants with non-dependent bipolar pacemakers were recruited from the pacemaker clinic at the Jewish General Hospital, whose research ethics board approved this study, and assessed it to be competent of consent by the treating physician. Participants were selected on two criteria: (1) reported subjective memory impairment and deemed likely to benefit from a tDCS treatment session, and (2) implanted with an artificial bipolar nondependent cardiac pacemaker. We chose participants with subjective memory impairments because we wanted to simulate the type of participant that would be enrolled in a tDCS study for people living with a neurodegenerative disease. Thus, we could carry out a study resembling an intervention treatment, which could then be replicated in future studies. Only participants with a Medtronic Sensia artificial cardiac pacemaker (dr or sr model), or a similar make and model, were recruited to ensure the pacemakers had internal memory that could be subsequently interrogated. As participants would be receiving tDCS, we excluded participants with any metal implants or shunts in their head as such factors can impact tDCS flow. Demographic information for the participants recruited is displayed in Table 1 .
tDCS parameters
In all tDCS sessions, a CE-certified DC-Stimulator MC (Neuro-Conn GmbH, Ilmenau, Germany) was used to administer tDCS for 30 min at 2 mA. To ensure impedance levels would be below 5.0 kU for all participants, where side-effects are perceived substantially less, syringes were used to apply further solution to the area underneath the sponges. At these low levels of impedance, participants quickly habituate to the feeling of stimulation. To indicate the location where electrodes would be subsequently placed, the location of the participant's left or right DLPFC was determined at
the beginning of each tDCS session using the EEG 10e20 system for standardized placement of electroencephalogram (EEG) electrodes. The 10e20 system correlates external skull locations to the underlying cortical areas and accounts for variability in patient skull size by using certain percentages of the circumference, as well as distances between four basic anatomical landmarks. The desired skull locations are found by using these measurements and relating them to the four landmarks [15] . In the current study, coordinates indicating the location of the left or right DLPFC were determined and marked with a pen as the location where the electrodes should be placed for that montage. Subsequently, for all montages, electrodes measuring 5 by 7 cm were placed vertically over the area marked with the pen (i.e., the left or right DLPFC), with the dot roughly in the center of the electrode. The electrodes would sit on the scalp within sponges that had been pre-soaked using syringes. Approximately 25 ml of saline (0.09%) was applied to each sponge just before the electrode was slipped within the sponge and placed on the participants' scalp. Rubber straps were used to secure the sponges in place. In two of three montages, the anode electrode was placed over the left or right DLPFC area with the cathode electrode over the contralateral deltoid muscle, which was held in place with an elastic bandage. Rather than using metal clips, the end of the elastic bandage was tucked under itself to be kept it in place. For the third montage, the cathode electrode was placed over the left DLPFC area and the anode electrode over the right deltoid muscle. Sham stimulation was never given and participants were told they would receive real tDCS stimulation in all three sessions because our interest was whether tDCS stimulation would interact with the implanted pacemaker.
Study design
The three tDCS montages (anode over left DLPFC and cathode over right deltoid; anode over right DLPFC and cathode over left deltoid; anode over right deltoid and cathode over left DLPFC) were counter-balanced across participants and given across three separate sessions. These sessions were scheduled on consecutive days during the week to minimize the time between the baseline interrogation of the pacemaker and the final interrogation of the pacemaker. In the first session, prior to receiving tDCS stimulation, the participant's pacemaker was interrogated with a Medtronic Carelink 2090 to obtain baseline readings.
Stimulation in each session began with the research assistant setting-up that session's tDCS montage as described in the previous section. Once tDCS stimulation was initiated, participants were asked to complete a flanker task [16] to alleviate boredom during stimulation. For this task, images were presented on a 15.6 00 DELL laptop using the display program PRESENTATION® (Version 18.0, Neurobehavioral Systems, Inc., Berkeley, CA, www.neurobs.com). In this task, an arrow pointing to the left or right appeared in the middle of the screen and participants had to press one button when the arrow was pointing left, but another button when the arrow was pointing right. Difficulty is introduced by having one to three additional arrows on both sides of the center arrow (i.e., the flanks) which are either pointing in the same direction as the center arrow (congruent condition) or pointing in the opposite direction (incongruent condition). Incongruent conditions are considered more difficult than congruent trials, especially if there are a maximum number of flanks present. It took participants roughly 10 min to complete this arrow version of the Flanker task. To ensure the task lasted the full 30 min of stimulation, an additional two versions were created using different stimuli. In the second version, the center image was either a rabbit or a hamster, with congruent and incongruent flanks that were either one to three rabbits or one to three hamsters on both sides of the center image. The two stimuli in the third version were an axe and a hammer, with corresponding flanks around the center image. Each version of the flanker task (arrow, animal, tool) lasted approximately 10 min and took participants the full 30 min of tDCS stimulation to complete. To maximize safety during stimulation, cardiac activity was monitored via continuous electrocardiogram (ECG) and pulse oximetry to monitor if a participant experienced a cardiac episode. Any observed abnormalities or fluctuations would be noted.
Immediately after the 30 min of tDCS was received in the third session (i.e., the participant's final session), the Medtronic Carelink 2090 was again used to interrogate the participant's pacemaker to check for any possible interference effects, and if any damage had occurred to the pacemaker. Note that the pacemakers involved in this study have continuous recording devices that are always on. To use an analogy, the pacemaker's recording device is like a security camera constantly filming the same location over the span of several days, and one can simply watch the recorded video after a number of days. Thus, at the end of the tDCS sessions in the present study, we were able to examine the recordings done across all three sessions and determine if there were interference effects during any of the sessions. For example, we would be able to determine if there had been an interference effect at session 1 or 3 from the interrogation report after the final session.
Interpreting the interrogation report
In simplest terms, pacemakers are used to maintain a heart's natural rhythm to ensure it doesn't beat too fast, too slowly, or irregularly [17] . To do so, electrodes on the heart send data through wires to a computer in the pacemaker, where a detected abnormal heart rate can trigger an electrical pulse from the pacemaker to the heart to regulate the detected beat [18e20]. Pacemakers can send impulses to the heart continuously to regulate the heart beat, in which case the person is considered pacemaker dependent, or on demand when the heart beat is irregular or too slow, in which case the person is considered non-dependent [21] . Under normal circumstances, mode switches in an interrogation report represent an occurrence where the pacemaker detected an abnormal heart beat (e.g., too slow) and responded with impulses designed to return the heart to a normal rhythm [22] . In other words, a mode switch in an interrogation report means the pacemaker responded to a sensed event. In the current study, in the absence of cardiac difficulty in the participant, such mode switches can be interpreted as the pacemaker responding to the transmission of tDCS. Thus, mode switches in the post-stimulation interrogation report were considered the best indication of the pacemaker sensing any unusual activity and would indicate if tDCS impacted the pacemaker. The pacemaker also monitors the heart rate by recording the heart's electrical activity, thresholds and impedance levels of the atrium and ventricles, which in addition to mode switches are recorded and saved by the computer in the pacemaker. Thus, any observed abnormal electrical activity is also recorded by the pacemaker and made available on subsequent interrogation reports. In a clinical context, doctors observing such fluctuations may decide to adjust the pacemakers' programming to improve its function for the person. In the present study, large deviations from baseline could be interpreted as the pacemaker responding to the presence of electrical activity from tDCS, which could subsequently interfere with the behaviour of the pacemaker and how it interprets the heart's electrical activity. Thus, to check if tDCS was interfering with pacemaker function, in addition to checking whether mode switches had occurred over the course of the three tDCS sessions, we observed if there had been any non-safe impendence levels recorded (i.e. smaller than 300 or larger than 2000 U; [23] .
Results
Parameters related to each participant's pacemaker are displayed in Table 2 .
No adverse events were observed during the stimulation sessions. More specifically, for both pulse oximetry and ECG during the tDCS sessions, there was normal oxygen saturation and heart rate with no abnormal fluctuations observed. As these tools were used as extra safety precaution, measures to ensure a safe experimental session rather than as a measurement, we planned to only record any fluctuations observed, but there were none. Thus, we have nothing to report other than the absence of any abnormalities during the tDCS sessions. After the third stimulation session, the pacemaker was interrogated and there were no parameter changes. Furthermore, there was an absence of mode switches in all of our participants (see Table 3 ). Thus, there was no evidence that tDCS provoked a change of programming in the pacemaker.
Recorded impedance levels were assessed in all seven participants and all remained within the safety threshold. Paired t-tests verified that pacemaker impendence levels were similar before and after stimulation. These measures are presented in Table 4 .
In summary, the results from study 1 found no interaction between tDCS stimulation and the functioning of the implanted pacemaker. Indeed, the pacemaker did not detect the presence of tDCS stimulation. To generalize these results to additional pacemaker types, we repeated the first study with participants who had bipolar dependent pacemakers. Based on the results found in study 1, we again expected tDCS would have an innocuous impact on participants' pacemakers.
Study 2: Bipolar dependent pacemakers
Material and methods
Two participants with bipolar dependent pacemakers were recruited from the pacemaker clinic at the Jewish General Hospital and assessed to be competent of consent by the treating physician. Participant selection was identical to study 1, except only participants with a bipolar dependent pacemaker were recruited. Cardiac activity was again carefully monitored via continuous electrocardiogram (ECG) and pulse oximetry to ensure the participants experienced no cardiac episodes during the sessions. Thus, the only difference in study 2 was the pacemakers being dependent rather than non-dependent. Initially, we aimed to recruit six participants to better match the sample size of study 1. Unfortunately, finding willing participants was difficult and we chose to cease recruitment after 18 months due to the consistency and robustness of the results found across participants in both studies. The parameters for participant's pacemakers are displayed in Table 5 .
Results
Parameters related to each participant's pacemaker are displayed in Table 6 .
As observed for non-dependent pacemakers, there were no adverse events during stimulation and post-stimulation interrogation of participants' pacemakers again found no parameter changes, as well as an absence of mode switches (see Table 7 ).
Thus, the results found no evidence that tDCS interferes with the functioning of pacemakers. For measured thresholds and impedance levels, there was again an absence of any significant difference, and impendence levels remained within the safety range. Results are displayed in Table 8 .
Discussion
In this initial proof of concept study, we examined whether tDCS can impact the proper functioning of pacemakers. As previously discussed, the current hypothesis is that tDCS can interfere with pacemaker function; however, supporting evidence to date had been weak to null. The present study found no evidence that tDCS interferes with a person's pacemaker. Bluntly, from the perspective The absence of irregular cardiac activity during tDCS sessions combined with an absence of mode switches or parameter changes suggests brain tDCS is innocuous for the proper functioning of pacemakers and such individuals may be included in studies where tDCS stimulation is given.
Conclusions
Further research and participants will be needed to replicate the preliminary results and verify the conclusion reached in this initial investigation. To be clear, the present study specifically finds that pacemakers are undisturbed in the short-term by tDCS when given for 30 min at 2 mA, even when one electrode is on the deltoid muscle. Long-term impact will require further investigation. It is also possible that the results would be different at larger intensities like 4 MA, as used in some studies [24] , or if delivered for longer than 30 min as some researchers have done [25] . Furthermore, some studies have reported that tDCS administered to specific brain regions can affect the parasympathetic and sympathetic branches of the autonomic nervous system, as well as heart rate [26e28]. We suspect, however, that tDCS would be safe even at 4 mA or for longer durations because the energy level transmitted by tDCS is extremely low and there are safety features implanted in pacemakers to safeguard against interference effects. Older pacemaker models are more likely to pose a risk, and it will be important to generalize the current results beyond bipolar pacemakers and those made by Medtronic. Affected heart rate may also be tolerable as pacemakers are programmed with maximum and minimum heart rate settings that dictates when the pacemaker will respond. For tDCS to be problematic for pacemakers due to a faster heart rate, the increase would have to be sufficient enough to exceed the programmed maximum, and present studies suggest tDCS is unable to change heart rate to this magnitude. It is also worth noting that none of the participants had heart rate escalations in the present study. Nevertheless, these questions will be important for future studies that will continue to examine if pacemakers should be an exclusion criterion for tDCS. With the world's population expected to become increasingly older (retrieved from United States Census Bureau, News Release e March 13th, 2018 [29] ), these studies will be crucial as the number of people with dementia who have pacemakers is expected to rise dramatically. Considering the possible benefits that tDCS therapy may provide, any associated exclusion criteria should be fully warranted to avoid denying possible succour.
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